keyword
MENU ▼
Read by QxMD icon Read
search

adherence treatment schizophrenia

keyword
https://www.readbyqxmd.com/read/27901520/depot-antipsychotics-where-do-we-stand
#1
Ahsan Y Khan, Salman Salaria, Muhammad Ovais, George D Ide
BACKGROUND: Nonadherence to medication is a major problem for patients with schizophrenia. To counter this problem, pharmaceutical companies began developing depot antipsychotics. Although there are currently 5 first-generation and 6 second-generation depot antipsychotics available worldwide, many physicians are still reluctant to use this category of drug initially. This review provides the latest information about the use of depot antipsychotics in schizophrenia treatment as well as several studies in support of depot antipsychotic use as first-line treatment for patients with schizophrenia...
November 2016: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/27888956/improving-adherence-in-hospitalized-patients-diagnosed-with-schizophrenia-an-integrative-one-on-one-intervention
#2
Sagit Dahan, Pnina Behrbalk, Tali Stolovy, Chaya Greenberger
OBJECTIVE: This study examined an individualized integrative nursing intervention for improving attitude and adherence. METHODS: The sample included 60 patients, randomly assigned to an experimental or control group. Measures included The Visual Analog Scale for Assessing Treatment Compliance and the Drug Attitude Inventory (DAI- 10). RESULTS: Significant differences were found in attitude and reported adherence for the experimental group, before and after...
December 2016: Archives of Psychiatric Nursing
https://www.readbyqxmd.com/read/27879426/the-successful-concurrent-use-of-two-long-acting-depot-antipsychotics-in-a-patient-with-treatment-resistant-schizophrenia-and-history-of-serious-violence-a-case-report
#3
Anna Lenardon, Mona Ahmed, Katie-Lynn Harfield, Mrigendra Das
OBJECTIVE: This case report describes a forensic psychiatric patient presenting with treatment-resistant schizophrenia and serious interpersonal violence complicated by poor adherence to oral medication who was treated successfully with two concurrent long-acting depot antipsychotics. METHOD: Treatment response was measured for a 6-month period at 6-weekly intervals, post-initiation using the Positive and Negative Symptoms of Schizophrenia with Excited Component score (PANSS-EC), Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression Scale (CGI)...
November 22, 2016: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/27872683/safe-and-effective-sofosbuvir-based-therapy-in-patients-with-mental-health-disease-on-hepatitis-c-virus-treatment
#4
Lydia Shuk Yee Tang, Jack Masur, Zayani Sims, Amy Nelson, Anu Osinusi, Anita Kohli, Sarah Kattakuzhy, Michael Polis, Shyam Kottilil
AIM: To study impact of baseline mental health disease on hepatitis C virus (HCV) treatment; and Beck's Depression Inventory (BDI) changes with sofosbuvir- and interferon-based therapy. METHODS: This is a retrospective cohort study of participants from 5 studies enrolled from single center trials conducted at the Clinical Research Center of the National Institutes of Health, Bethesda, MD, United States. All participants were adults with chronic HCV genotype 1 infection and naïve to HCV therapy...
November 8, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27871302/glycopyrrolate-in-comparison-to-hyoscine-hydrobromide-and-placebo-in-the-treatment-of-hypersalivation-induced-by-clozapine-gothic1-study-protocol-for-a-randomised-controlled-feasibility-study
#5
Inti Qurashi, Simon Chu, Nusrat Husain, Richard J Drake, Imran Chaudhry, J F W Deakin
BACKGROUND: Clozapine is the only medication licensed for the treatment of resistant schizophrenia in the UK. Although efficacious, a common and unpopular side effect of clozapine treatment is clozapine-induced hypersalivation (CIH), which can contribute to non-adherence. The standard treatment for CIH in the UK is hyoscine hydrobromide but this may aggravate cognitive deficits in patients with schizophrenia while glycopyrrolate may be an effective alternative with a more tolerable side effect profile...
November 21, 2016: Trials
https://www.readbyqxmd.com/read/27869872/-towards-dsm-5-1-proposals-for-schizophrenia
#6
Cinzia Niolu, Emanuela Bianciardi, Michele Ribolsi, Alberto Siracusano
Schizophrenia is a debilitating illness, present in approximately 1% of the global population. It is manifested through positive symptoms including delusions, hallucinations, disorganized thoughts and negative symptoms such as avolition, alogia, and apathy. In 2013 the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has been released and some changes were introduced to make diagnosis of schizophrenia more accurate and precise, but researchers are already studying how to improve again the diagnostic criteria of this disorder...
November 2016: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/27860369/factor-structure-of-therapist-fidelity-to-individual-resiliency-training-in-the-recovery-after-an-initial-schizophrenia-episode-early-treatment-program
#7
Julia Browne, Alexandra N Edwards, David L Penn, Piper S Meyer-Kalos, Jennifer D Gottlieb, Paul Julian, Kelsey Ludwig, Kim T Mueser, John M Kane
BACKGROUND: Evidence-based approaches and early intervention have improved the long-term prognosis of individuals with schizophrenia. However, little is known about the therapeutic processes involved in individual therapy in first-episode psychosis. A comprehensive psychosocial/psychiatric programme for this population, NAVIGATE, includes an individual therapy component, individual resiliency training (IRT). Fidelity of clinicians' adherence to the IRT protocol has been collected to ensure proper implementation of this manual-based intervention...
November 9, 2016: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/27851771/the-impact-of-stakeholder-preferences-on-service-user-adherence-to-treatments-for-schizophrenia-and-metabolic-comorbidities
#8
Daniel Poremski, Vathsala D/O Sagayadevan, Peizhi Wang, Alvin Lum, Mythily Subramaniam, Chong Siow Ann
OBJECTIVE: To determine how stakeholder opinions of treatments influence service user decisions to adhere to courses of actions necessary to treat metabolic conditions. METHODS: Qualitative open-ended interviews were conducted with 20 service providers, 25 service users, and 9 caregivers. Grounded theory was used to generate an understanding that linked preferences of care with adherence to follow-up treatments. RESULTS: Participants spoke about several considerations when discussing adherence: Resource limitations were the predominant consideration...
2016: PloS One
https://www.readbyqxmd.com/read/27842941/the-impact-of-second-generation-antipsychotics-on-insight-in-schizophrenia-results-from-14-randomized-placebo-controlled-trials
#9
Taina Mattila, Maarten Koeter, Tamar Wohlfarth, Jitschak Storosum, Wim van den Brink, Eske Derks, Hubertus Leufkens, Damiaan Denys
Despite the negative impact of lack of insight on the prognosis, general functioning and treatment adherence, the effect of antipsychotic medication on insight has been investigated only in small samples and uncontrolled studies. In this study we examine whether previously reported effects of antipsychotics on insight from uncontrolled studies can be confirmed in a database including 14 randomized, double-blind, placebo-controlled trials. The database contained placebo-controlled RCTs of five second-generation antipsychotics (SGAs: olanzapine, paliperidone, quetiapine, risperidone and sertindole) and included a total of 4243 patients with schizophrenia...
November 11, 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27833241/reasons-for-schizophrenia-patients-remaining-in-out-or-on-treatment-non-adherence-to-clarity
#10
Harshini Manohar, Shivanand Kattimani
No abstract text is available yet for this article.
September 2016: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/27815512/schizophrenia-impact-of-psychopathology-faith-healers-and-psycho-education-on-adherence-to-medications
#11
Karim Abdel Aziz, Mohammed H Elamin, Nisrin M El-Saadouni, Dina Aly El-Gabry, Mahmoud Barakat, Fatima Alhayyas, Hamdy F Moselhy
BACKGROUND: Many patients suffering from psychosis are nonadherent to their medications. Nonadherence can range from treatment refusal to irregular use or partial change in daily medication doses. AIM: To investigate whether symptom dimensions, post-discharge care plans and being involved with faith healer affect the adherence to treatment in patients with schizophrenia. METHOD: A total of 121 patients with schizophrenia were examined 6 weeks post-discharge from the inpatient unit and assessed for full, partial or nonadherence to medication...
December 2016: International Journal of Social Psychiatry
https://www.readbyqxmd.com/read/27811454/sociodemographic-and-clinical-correlates-of-sexual-dysfunction-among-psychiatric-outpatients-receiving-common-psychotropic-medications-in-a-neuropsychiatric-hospital-in-northern-nigeria
#12
V O Olisah, T L Sheikh, E R Abah, A F Mahmud-Ajeigbe
BACKGROUND: Sexual dysfunction is common in patients receiving psychotropic medications and may reduce their quality of life and medication adherence with resultant negative impact on treatment outcomes. OBJECTIVES: In this study, we described the various types of sexual dysfunction among psychiatric outpatients receiving psychotropic medications and the sociodemographic and clinical correlates associated with it. SETTINGS AND DESIGN: A descriptive, cross-sectional study conducted in a Neuropsychiatric Hospital in Northern Nigeria...
November 2016: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/27799749/physician-and-patient-benefit-risk-preferences-from-two-randomized-long-acting-injectable-antipsychotic-trials
#13
Eva G Katz, Brett Hauber, Srihari Gopal, Angie Fairchild, Amy Pugh, Rachel B Weinstein, Bennett S Levitan
PURPOSE: To quantify clinical trial participants' and investigators' judgments with respect to the relative importance of efficacy and safety attributes of antipsychotic treatments for schizophrenia, and to assess the impact of formulation and adherence. METHODS: Discrete-choice experiment surveys were completed by patients with schizophrenia and physician investigators participating in two phase-3 clinical trials of paliperidone palmitate 3-month long-acting injectable (LAI) antipsychotic...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27789187/validation-study-of-the-medication-adherence-rating-scale-results-from-the-face-sz-national-dataset
#14
Guillaume Fond, Laurent Boyer, Mohamed Boucekine, Latif A Aden, Franck Schürhoff, Arnaud Tessier, Meja Andrianarisoa, Fabrice Berna, Lore Brunel, Delphine Capdevielle, Isabelle Chereau, Jasmina Mallet, Hélène Denizot, Jean Michel Dorey, Caroline Dubertret, Julien Dubreucq, Catherine Faget, Franck Gabayet, Romain Rey, Raphaelle Richieri, Christine Passerieux, Aurélie Schandrin, Mathieu Urbach, Pierre Vidailhet, Pierre Michel Llorca, David Misdrahi
OBJECTIVE: The Medication Adherence Rating Scale (MARS) is one of the most widely used measurements of adherence in schizophrenia (SZ). However, the data available regarding its psychometric properties are scarce. The aim of this study was to provide new data regarding the psychometric properties of the MARS in a multicenter community-dwelling sample of SZ patients. METHODS: This study was conducted in the French National network of the 10 FondaMental Expert Centers for SZ...
October 24, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27783555/integrated-pharmacies-at-community-mental-health-centers-medication-adherence-and-outcomes
#15
W Abel Wright, Jack M Gorman, Melissa Odorzynski, Mark J Peterson, Carol Clayton
BACKGROUND: Patients receiving psychiatric services at community mental health centers (CMHCs) are often prescribed medication that is critical to the treatment of behavioral health conditions, including schizophrenia, bipolar disorder, anxiety, and depression. Previous studies have shown correlation between rates of medication adherence and risk of hospitalization, but potential differences in medication adherence and other outcomes for patients of CMHCs by pharmacy type have not been widely studied...
November 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27783548/patterns-of-adherence-to-oral-atypical-antipsychotics-among-patients-diagnosed-with-schizophrenia
#16
Joanna P MacEwan, Felicia M Forma, Jason Shafrin, Ainslie Hatch, Darius N Lakdawalla, Jean-Pierre Lindenmayer
BACKGROUND: Poor medication adherence contributes to negative treatment response, symptom relapse, and hospitalizations in schizophrenia. Many health plans use claims-based measures like medication possession ratios or proportion of days covered (PDC) to measure patient adherence to antipsychotics. Classifying patients solely on the basis of a single average PDC measure, however, may mask clinically meaningful variations over time in how patients arrive at an average PDC level. OBJECTIVE: To model patterns of medication adherence evolving over time for patients with schizophrenia who initiated treatment with an oral atypical antipsychotic and, based on these patterns, to identify groups of patients with different adherence behaviors...
November 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27783545/estimating-the-value-of-new-technologies-that-provide-more-accurate-drug-adherence-information-to-providers-for-their-patients-with-schizophrenia
#17
Jason Shafrin, Taylor T Schwartz, Darius N Lakdawalla, Felicia M Forma
BACKGROUND: Nonadherence to antipsychotic medication among patients with schizophrenia results in poor symptom management and increased health care and other costs. Despite its health impact, medication adherence remains difficult to accurately assess. New technologies offer the possibility of real-time patient monitoring data on adherence, which may in turn improve clinical decision making. However, the economic benefit of accurate patient drug adherence information (PDAI) has yet to be evaluated...
November 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27777062/effectiveness-efficiency-and-efficacy-in-the-multidimensional-treatment-of-schizophrenia-rethinking-project
#18
Benedicto Crespo-Facorro, Miguel Bernardo, Josep Maria Argimon, Manuel Arrojo, Maria Fe Bravo-Ortiz, Ana Cabrera-Cifuentes, Julián Carretero-Román, Manuel A Franco-Martín, Paz García-Portilla, Josep Maria Haro, José Manuel Olivares, Rafael Penadés, Javier Del Pino-Montes, Julio Sanjuán, Celso Arango
Schizophrenia is a clinically heterogeneous syndrome affecting multiple dimensions of patients' life. Therefore, its treatment might require a multidimensional approach that should take into account the efficacy (the ability of an intervention to get the desired result under ideal conditions), the effectiveness (the degree to which the intended effect is obtained under routine clinical practice conditions or settings) and the efficiency (value of the intervention as relative to its cost to the individual or society) of any therapeutic intervention...
October 22, 2016: Revista de Psiquiatrí́a y Salud Mental
https://www.readbyqxmd.com/read/27766621/through-the-looking-glass-estimating-effects-of-medical-homes-for-people-with-severe-mental-illness
#19
Marisa Elena Domino, Mona Kilany, Rebecca Wells, Joseph P Morrissey
OBJECTIVE: To examine whether medical homes have heterogeneous effects in different subpopulations, leveraging the interpretations from a variety of statistical techniques. DATA SOURCES/STUDY SETTING: Secondary claims data from the NC Medicaid program for 2004-2007. The sample included all adults with diagnoses of schizophrenia, bipolar disorder, or major depression who were not dually enrolled in Medicare or in a nursing facility. STUDY DESIGN: We modeled a number of monthly service use, adherence, and expenditure outcomes using fixed effects, generalized estimating equation with and without inverse probability of treatment weights, and instrumental variables analyses...
October 21, 2016: Health Services Research
https://www.readbyqxmd.com/read/27755220/time-to-first-discontinuation-adherence-and-persistence-in-new-users-of-second-generation-antipsychotics
#20
Henry C Ndukwe, Prasad S Nishtala
Consensus guidelines which are applicable in New Zealand and worldwide recommend that the duration of exposure to antipsychotics not exceed 12 weeks, unless justified for mental illnesses like schizophrenia and severe psychotic symptoms which require longer treatment. There has been limited information on time-to-first discontinuation (TTFD) for second-generation antipsychotics (SGAs) in a real world population setting in older people. The study objective was to compare TTFD, adherence, and persistence for individual SGA new users among people 65 years and older...
December 2016: Journal of Clinical Psychopharmacology
keyword
keyword
110266
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"